Note: Ingredients listed on restricted chemical lists
EC/CAS
215-185-5/1310-73-2
Name of the chemical
sodium hydroxide
Concentration
>=0,5-<1 >=5% 2-<5% 0,5-<2% 0,5-<2%
General Information
Version
6.0
Revision date
2024-08-29
Product name
Micardis Plus tablets
1.2.1 Relevant identified uses
Pharmaceutical
1.2.2. Uses advised against
Safety Data Sheet only for the professional user on use
Emergency telephone
+498007790900, +1 703-527-3887, +49800 1817059
Icons in SDS
Company Information
company name
Boehringer Ing. Pharma GmbH & Co. KG
e-mail address of the competent person responsible for the Safety Data Sheet
EHS-Services@Boehringer-Ingelheim.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H315, H319, H350, H361d, H373, H412
Hazard statements
Code
Statements
H315
Causes skin irritation
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
Danger
Hazard statements
H315 Causes skin irritation. H319 Causes serious eye irritation. H350 May cause cancer. H361d Suspected of damaging the unborn child. H373 May cause damage to organs (Stomach, Kidney) through prolonged or repeated exposure. H412 Harmful to aquatic life with long lasting effects.
Prevention
P201 Obtain special instructions before use. P260 Do not breathe dust. P264 Wash skin thoroughly after handling. P273 Avoid release to the environment. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.
Response
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Hazardous Ingredients
Telmisartan hydrochlorothiazide
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumula- tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regu- lation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher. This drug is not subject to the labelling requirements under the Globally Harmonized System (GHS) The pharmacological effect of the medicament has to be considered (see package leaflet).
2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008) Skin irritation, Category 2 H315: Causes skin irritation. Eye irritation, Category 2 H319: Causes serious eye irritation. Carcinogenicity, Category 1A H350: May cause cancer. Reproductive toxicity, Category 2 H361d: Suspected of damaging the unborn child. Specific target organ toxicity - repeated H373: May cause damage to organs through pro- exposure, Category 2, Stomach, Kidney longed or repeated exposure. Long-term (chronic) aquatic hazard, Cat- H412: Harmful to aquatic life with long lasting ef- egory 3 fects.
